Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis

To investigate pneumothorax patterns in pazopanib treatment by focusing on the positional relationship between the visceral pleura and metastatic lung tumor, we examined 20 patients with advanced soft tissue tumors who developed lung metastases and underwent pazopanib treatment between 2012 and 2019. Pneumothorax was classified into two types based on the location of the metastatic lesion around the visceral pleural area before pazopanib treatment: subpleural type, within 5 mm from the pleura; and central type, >5 mm from the pleura. We investigated the rates of pneumothorax and the associated risk factors. Five patients experienced pneumothorax (three subpleural and two central types). Cavitation preceded pneumothorax in 83% of patients and led to connection of the cavitated cyst of the metastatic lesion to the chest cavity in the shorter term in patients with the subpleural type. Conversely, a more gradual increase in the cavity size and sudden cyst rupture were observed in the central type. The risk factors for pneumothorax were cavitation after initiating pazopanib and intervention before pazopanib, either ablation or surgery. The location of the metastatic lesions was not a risk factor for the occurrence of pneumothorax. In conclusion, pneumothorax is an adverse event associated with pazopanib treatment. Therefore, attention must be paid to predisposing factors such as the formation of cavitation after pazopanib initiation and previous interventions to the lungs. Moreover, because subpleural pneumothorax tends to occur earlier than the central type, a different time course can be anticipated based on the positional relationships of the metastatic lesions to the visceral pleura.

[1]  V. Yilmaz,et al.  A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment. , 2018, Turkish thoracic journal.

[2]  B. Sangro,et al.  Pneumatocele during sorafenib therapy: first report of an unusual complication , 2017, Oncotarget.

[3]  K. Katono,et al.  Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature , 2017, Case Reports in Oncology.

[4]  N. Araki,et al.  The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study , 2016, Cancer.

[5]  J. Sandoval,et al.  Pneumothorax as a Complication of Combination Antiangiogenic Therapy in Children and Young Adults with Refractory/Recurrent Solid Tumors , 2015, Journal of pediatric surgery.

[6]  H. Gelderblom,et al.  Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series , 2014, Clinical Sarcoma Research.

[7]  S. Matsumoto,et al.  Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[9]  A. Suttle,et al.  Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[11]  A. Arnold,et al.  Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[12]  L. Seymour,et al.  Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Grasemann,et al.  Necrotizing pneumonia complicated by early and late pneumatoceles. , 2008, Canadian respiratory journal.

[14]  G. Gladish,et al.  Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Y. Kotoura,et al.  Pulmonary cysts as the sole metastatic manifestation of soft tissue sarcoma: case report and consideration of the pathogenesis. , 1999, Chest.

[16]  T. Soulsby British Thoracic Society guidelines for the management of spontaneous pneumothorax: do we comply with them and do they work? , 1998, Journal of accident & emergency medicine.

[17]  R. Fraser,et al.  Pulmonary pneumatocele: pathology and pathogenesis. , 1988, AJR. American journal of roentgenology.

[18]  G. Boisset,et al.  Subpleural emphysema complicating staphylococcal and other pneumonias. , 1972, The Journal of pediatrics.